A minor E-selectin ligand, CD65, is critical for extravascular infiltration of acute myeloid leukemia cells

M Noguchi1, N Sato, H Sugimori

  • 1Department of Hematology, Juntendo University, School of Medicine, 2-1-1 Hongo, Bunkyo-ku, 113-8421, Tokyo, Japan.

Leukemia Research
|September 5, 2001
PubMed

Insights

Adhesive molecules on acute myeloid leukemic (AML) cells may drive infiltration. CD65 expression was identified as a key independent risk factor for extravascular infiltration in AML patients.

Area of Science:

  • Hematology
  • Immunology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
  • Leukemic cell adhesion and infiltration are critical for disease progression and extramedullary spread.
  • Understanding the molecular mechanisms of AML cell adhesion is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role of adhesion antigens in the extravascular infiltration of acute myeloid leukemic (AML) blasts.
  • To identify specific adhesion molecules associated with increased infiltration in AML patients.

Main Methods:

  • Analysis of adhesion antigen expression and density on AML blasts from 30 patient samples.
  • Univariate and multivariate statistical analyses to correlate antigen profiles with extravascular infiltration.

Main Results:

  • Patients with extravascular infiltration exhibited significantly higher expression of multiple adhesion antigens, including CD2, CD11a, CD11b, CD11c, CD15, CD65, CD86, and HLA-DR.
  • Higher density of CD11a, CD11b, CD11c, CD15, and CD65 expression was observed in patients with infiltration.
  • Multivariate analysis identified CD65 as the sole significant independent risk factor for extravascular infiltration.

Conclusions:

  • CD65 is a critical adhesion molecule mediating extravascular infiltration in acute myeloid leukemia.
  • Targeting CD65 may represent a novel therapeutic strategy to inhibit AML spread and improve patient outcomes.